Cambridge Isotope Laboratories, Inc. Announces Expansion of 13C Capacity at Ohio Plant

USA - English

• India - English

TEWKSBURY, Mass., Aug. 12, 2020 /PRNewswire/ -- Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotope chemistry and the separation of carbon-13 (¹³C), recently completed a significant expansion of its ¹³C separation facility. In 1987, CIL took the initiative to construct the world's largest ¹³C isotope-separation plant, Cambridge Isotope Separations, LLC (CIS), located on 33 acres in Xenia, Ohio.¹³C is a critical starting material supporting development of new research and diagnostic chemicals.  Following expansions in 1996, 2012, and 2015, CIL embarked on a new expansion in 2018 which was completed earlier this year. This most recent expansion increased production capacity of ¹³C by 25%.

"CIL has been investing and growing with customers continuously for the past 33 years," states Cliff Caldwell, CEO. "Our isotope markets have been expanding, and the volumes required by our committed customers have made it necessary that we continue to expand to meet the market needs. Cambridge Isotope Labs has many years of experience designing and building carbon isotope-separation systems and we are the leading technology expert in that space. This in-house knowhow makes us the supplier of choice because of the certainty we can reliably scale our production processes quickly and effectively." 

"The expansion was initiated in response to the strong and growing demand by our customers for ¹³C and ¹³C urea," says Mike Steiger, VP of Project Engineering and Execution. "There is an increasing need for isotopes for medical investigations and ¹³C plays an important role." The ¹³C isotope is known to be used in a variety of applications for environmental analysis, medical research, and medical diagnostics. Medical diagnosis-based CO₂ breath tests, such as ¹³C urea (used to detect Helicobacter pylori bacterial infection) and ¹³C methacetin for liver disease, can aid in the prevention of invasive procedures. 

¹³C is a nonradioactive (stable) element which makes up approximately 1% of all carbon atoms in nature. At the CIS plant in Ohio, natural carbon monoxide (containing ~1% ¹³C) is cryogenically liquefied and then distilled through several long specially designed distillation columns, which make it one of the world's longest distillation systems of any kind. CIL has continuously demonstrated its expertise in the area of cryogenic distillation and maintain our place as the world's leading producer of ¹³C isotope. The end-product of this process is carbon monoxide that is greater than 99% ¹³C, which is then used to manufacture any one of the thousands of isotope-labeled products offered by CIL. 

About Cambridge Isotope Laboratories, Inc.  

CIL is the world's largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL is an operating business owned by Otsuka Pharmaceuticals. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France.  

For more information on CIL, visit isotope.com.  

Related Images

image1.jpg

SOURCE Cambridge Isotope Laboratories, Inc.